B+
Bull case
20%
Probability
Target price
$5.40
+74.2% vs current
FATE
Fate TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.30
+6.5% vs current
B-
Bear case
30%
Probability
Target price
$1.75
-43.5% vs current
AI sentiment snapshot
Latest data as of 2026-07-18
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+62.7
Score
AI commentary
News tone is modestly positive after the reported July 9 FDA-related move and roughly 6% share-price reaction [#SERP-1]. Social and analyst-revision data are unavailable, and the peer set is weak, so sentiment remains a cautious monitoring signal rather than confirmation of a durable re-rating.
RankAlpha Sentiment Codex - 2026-07-18
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-16eventRECLAIM-LN Phase 2 initiationHigh impact
Fate expects to begin dosing its approximately 53-patient, potentially registrational RECLAIM-LN Phase 2 trial of FT819 in lupus nephritis during the second half of 2026. The trial's primary endpoint is complete renal response at six months [#SEC-8K-2026-05-13].
2026-10-16catalystFDA-related clinical-entry follow-throughHigh impact
A July 9 trusted-news item reported a roughly 6% share-price jump after FDA clearance to move a Fate cell-therapy program into clinical trials. The packet lacks the underlying company release, so this remains a lower-confidence momentum catalyst supported only directionally by Fate's prior disclosure that next-generation CAR-T programs were entering clinical trials [#SERP-1] [#SEC-8K-2026-05-13].
2027-07-18catalystFT819 regulatory and CMC pathway executionHigh impact
FT819's FDA CDRP selection and existing RMAT designation may improve regulatory and manufacturing communication, but value creation still depends on clinical execution and readiness [#SEC-8K-2026-05-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology